trending Market Intelligence /marketintelligence/en/news-insights/trending/ALSCL05paC4vZv7DQRgx-Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Deciphera looking to raise $200M after clinical trial win

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Deciphera looking to raise $200M after clinical trial win

Deciphera Pharmaceuticals Inc. said Aug. 13 that it was looking to raise $200 million, the same day it posted strong results from a study of its cancer drug ripretinib, which resulted in an increase in the company's stock price.

The underwritten offering is going to help raise funds for the continued development of Deciphera's cancer drugs ripretinib and rebastinib. Based on the recently released results, ripretinib was found to benefit patients with advanced gastrointestinal stromal tumors.

Funds will be used for additional studies of ripretinib and continued research of rebastinib, among other things.

J.P. Morgan, Piper Jaffray and Jefferies are the joint book-running managers for the offering. The Waltham, Mass.-based biotechnology company plans to give the underwriters a 30-day option to purchase an additional $30 million in common shares.